NGD.TO vs. CPRX

Last updated Jun 4, 2026

NGD.TO (New Gold Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. NGD.TO operates in Gold (Basic Materials), while CPRX operates in Biotechnology (Healthcare). At a 0.04 correlation, their price movements are largely independent.

Performance

NGD.TO vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in New Gold Inc. (NGD.TO) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

NGD.TO is traded in CAD, while CPRX is traded in USD. To make them comparable, the CPRX values have been converted to CAD using the latest available exchange rates.

Returns By Period

NGD.TO

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CPRX

• 1D: 0.44%
• 1M: 10.24%
• YTD: 35.73%
• 6M: 34.89%
• 1Y: 27.19%
• 3Y*: 41.01%
• 5Y*: 45.73%
• 10Y*: 49.31%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NGD.TO vs. CPRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NGD.TO New Gold Inc.	1.67%	233.15%	86.98%	44.36%	-29.63%	-32.50%	143.48%	9.52%	-74.58%	-12.31%
CPRX Catalyst Pharmaceuticals, Inc.	35.73%	6.71%	34.82%	-11.61%	194.32%	100.86%	-12.44%	85.71%	-46.73%	248.67%

Correlation

The correlation between NGD.TO and CPRX is -0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.06
Correlation (5Y) Calculated over the trailing 5-year period	0.11
Correlation (10Y) Calculated over the trailing 10-year period	0.08
Correlation (All Time) Calculated using the full available price history since Jun 23, 2009	0.04

The correlation between NGD.TO and CPRX shifts across timeframes, from -0.06 (1 year) to 0.11 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap NGD.TO : CA$9.63B CPRX : $3.97B
EPS NGD.TO : CA$1.09 CPRX : $1.74
PE Ratio NGD.TO : 11.16 CPRX : 17.98
PEG Ratio NGD.TO : 0.02 CPRX : 0.32
PS Ratio NGD.TO : 6.49 CPRX : 6.67
PB Ratio NGD.TO : 5.04 CPRX : 3.92
Total Revenue (TTM) NGD.TO : CA$1.49B CPRX : $596.96M
Gross Profit (TTM) NGD.TO : CA$767.09M CPRX : $378.23M
EBITDA (TTM) NGD.TO : CA$810.05M CPRX : $313.50M

Return for Risk

NGD.TO vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX

CPRX Risk / Return Rank: 60
CPRX Sharpe Ratio Rank: 65
CPRX Sortino Ratio Rank: 59
CPRX Omega Ratio Rank: 59
CPRX Calmar Ratio Rank: 60
CPRX Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NGD.TO vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for New Gold Inc. (NGD.TO) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	NGD.TO	CPRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.82	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.99	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.83	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.28	—

Drawdowns

Drawdown Indicators

	NGD.TO	CPRX	Difference
Max Drawdown Largest peak-to-trough decline	—	-90.42%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-25.85%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-27.61%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-45.04%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-62.68%	—
Current Drawdown Current decline from peak	—	0.00%	—
Average Drawdown Average peak-to-trough decline	—	-36.56%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	14.20%	—

Volatility

Volatility by Period

	NGD.TO	CPRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	6.78%	—
Volatility (6M) Calculated over the trailing 6-month period	—	23.33%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	33.36%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	46.54%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	59.67%	—

Dividends

NGD.TO vs. CPRX - Dividend Comparison

Neither NGD.TO nor CPRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NGD.TO and CPRX in my portfolio?

NGD.TO and CPRX have a correlation of -0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.